tbuckley/cabot-search huggingface dataset:
Crosstown Street
Authors: Thomas B. Cole
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FRI0518 Update on Results of the Uveitis Outcome Validation Study from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (Miwguc)
Authors: I. Foeldvari, S. Schenk, G. Simonini, C. de Libero, G. Brumm, K. Kotaniemi, S. Nielsen, R. Bangsgaard, I. Pontikaki, V. Gerloni, E. Miserocchi, M. Niewerth, A. Heiligenhaus
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Juvenile idiopathic arthritis (JIA) associated uveitis is one of the most severe comorbidities and occurs in around 10% of patients. There are currently no specific established outcome measures for JIA associated uveitis (JIAU). The SUN group made the first attempt to establish outcome measures for uveitis, which were not aimed at JIAU. Adopting part of it, we developed and proposed specific outcome measures for JIAU. Here we are presenting the results of the validation study. <h3>Objectives</h3> To prospectively validate the proposed outcome measures, if they fulfil the expected OMERACT criteria. <h3>Methods</h3> Patients were considered eligible, if they started a nonbiologic or biologic disease modifying agent, as indicated by active the uveitis. At baseline, follow up at 3 months and at 6 months following parameters were collected: demographics, rheumatologic assessment (JIA type, activity of arthritis, JIA-related disability), ophthalmologic assessment (duration of uveitis, activity and damage of uveitis, visual acuity, ocular complications, topical and systemic medications, surgical procedure, uveitis-related disability). <h3>Results</h3> 49 patients were included in the study and 35 patients had a complete follow-up for at least at 6 months. 34/49 (69%) of the patients were female. The mean age at inclusion into the study was 8.4 years (SD=3.4). 98% of the patients were Caucasian. At inclusion the median disease duration of JIA was 52 months for arthritis and 33 months for uveitis. All patients had anterior uveitis. The left eye was more frequently involved (95.3%) then the right eye (81%). Cellcount at baseline was +1 or more in 65.1% of the right eyes and 68.9% of the left eyes, and at 6 months only 22.6% in the right and 19.3% in the left eyes. The cell count before dilatation (p=0.008) and after dilatation (p&lt;0.001) improved significantly over time. Flare was ≥1+ (graded by SUN) at baseline in the right eyes in 76.7% and in the left eyes 70.2% and at 6 months at the right eyes in 24.1% and the left eyes in 24.1%. The flare grade according SUN (p&lt;0.001) improved significantly comparing time point zero to 6 months. The VAS score (0-100) for uveitis related disability decreased from 40.8 to 17.5 (p=0.002) and JIA associated disability, decreased from 34.1 to 8.3 (p&lt;0.001). <h3>Conclusions</h3> These results regarding the standardized assessment of the JIAU are promising. The newly suggested Uveitis disability, cell count and flare grade showed significant changes after 6 months. Further evaluation of these items and the other suggested items will help to establish standardized measures to assess the activity of uveitis and the efficacy of a drug in treatment trials. <h3>Disclosure of Interest</h3> None declared
An attempt to objectify the therapeutic process: a working model
Authors: L Karme, S Cooperman, T Preston
Journal: American Journal of Psychiatry (1979)

On the basis of their observations in daily psychoanalytic work the authors developed five objective criteria for "bad" analytic hours. These criteria involve affect, intellectualization, isolation, lack of feedback, and dissatisfaction. The authors developed a formulation to help them preconsciously recognize the presence of these factors during therapeutic work and found that it was helpful in turning a potentially bad hour into a productive one.
AB0819 Axial Psoriatic Arthritis with and Without Radiological Involvement: Are There Any Differences?: Table 1
Authors: M. Almirall, T.C. Salman, M.P. Lisbona, S. Iniesta, J. Maymό
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> CASPAR criteria for psoriatic arthritis (PsA) classification have as entry criteria inflammatory articular disease (joint, spine or entheseal). In 2009 Grappa group proposed diagnostic criteria for axial PsA, which include radiological involvement (non mandatory point). <h3>Objectives</h3> The aim of this study was to evaluate differences between patients with axial Apso with and without radiological involvement in spine and/or sacroiliac joints. <h3>Methods</h3> Descriptive, observational study, selecting consecutive patients from our department of Rheumatology with PsA fulfilling CASPAR criteria with axial involvement (Grappa criteria) with disease duration ≥5 years in 2013. Patients were divided in two groups, radiographic and non-radiographic axial PsA, according to the presence of suggestive radiology (unilateral or bilateral sacroiliitis grade 2 or more and/or syndesmophytes in spine). Differences in clinical, laboratory and radiological variables between patients with radiographic and non-radiographic axial PsA were evaluated. The variables assessed were: age, sex, disease duration, history/presence of peripheral involvement (arthritis, enthesitis or dactylitis), pattern of arthritis (oligoarticular or polyarticular), uveitis, family history of spondyloarthritis (including psoriatic arthritis) and/or psoriasis, therapy with synthetic disease-modifying antirheumatic drugs (sDMARD), with biologic disease-modifying antirheumatic drugs (bDMARD), with ≥2 bDMARD, HLAB27 positivity, history/presence of high CRP and/or ESR levels (CRP&gt;0.6mg/dl and ESR&gt;20mm/hour) and erosions in hands and/or feet in X-rays. The differences in baseline characteristics between both groups of patients were calculated by <i>Student9s t-test</i> for quantitative variables and Chi-Square test for categorical variables. <h3>Results</h3> Significantly more patients had oligoarticular pattern and family history of psoriasis in radiographic axial PsA group vs non-radiographic axial group (70.6% vs 25%, p=0.002 and 67.6% vs 37.5%, p=0.044). There were no statistically significant differences in other variables evaluated between two groups of axial PsA: radiographic and non-radiographic. <h3>Conclusions</h3> The only statistically significant differences among patients with radiographic and non- radiographic axial PsA were the pattern of peripheral involvement and family history of psoriasis. <h3>Disclosure of Interest</h3> None declared
Current state of concussion prevention strategies: a systematic review and meta-analysis of prospective, controlled studies
Authors: Daniel K Schneider, Ravi K Grandhi, Purnima Bansal, George E Kuntz, Kate E Webster, Kelsey Logan, Kim D Barber Foss, Gregory D Myer
Journal: British Journal of Sports Medicine (2016)

Objective The aim of the current review was to systematically identify, evaluate and synthesise trials that examine concussion prevention via equipment, educational programmes and training programmes. Data sources PubMed and EBSCO host (CINAHL, MEDLINE, SPORTDiscus). Eligibility criteria for selecting studies The electronic databases PubMed and EBSCO were searched using the phrases: concussion prevention equipment , concussion prevention training and concussion prevention education . Included studies utilised a prospective study design to evaluate the preventative effect of: (1) equipment, (2) training or (3) educational programmes on the incidence of concussions in comparison to a control group. Data extraction Demographic data and intervention methods were recorded. Intervention and control group concussion rates and superficial head injury rates were extracted and combined using random-effects relative risk meta-analysis. Results 14 studies evaluated interventions of novel protective equipment. One prospective investigation evaluated an educational programme. The relative risk of concussion for participants enrolled in the interventional arms of trials was not significantly different from that in standard practice arms (RR=0.78, 95% CI 0.55 to 1.11, χ 2 =1.8, p=0.17; I 2 =85.3%, 95% CI 71.5% to 90.8%). The relative risk of concussion for participants wearing protective equipment (ie, headgear, full face shields) relative to their counterparts wearing standard or no equipment, calculated from seven available reports, showed no effect of intervention (RR=0.82, 95% CI 0.56 to 1.20, χ 2 =1.06, p=0.30; I 2 =86.7%, 95% CI 73.3% to 91.8%). The relative risk of superficial head injury for participants wearing protective equipment relative to their counterparts, calculated from three reports, showed a significant risk reduction (RR=0.41, 95% CI 0.31 to 0.56, χ 2 =34.13, p&lt;0.0001; I 2 =53.1%, 95% CI 0% to 85.2%). Conclusions Prospective controlled studies indicate that certain protective equipment may prevent superficial head injury, but these items are suboptimal for concussion prevention in sport.
AB0059 Increased Serum Interleukin9 Levels in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Pathogenic Role or Just an Epiphenomenon?
Authors: A.T. Dantas, C.D.L. Marques, L.F. Rocha Junior, M.B. Cavalcanti, S.M.C. Gonçalves, P.R.G. Cardoso, H.A. Mariz, A.L.B.P. Duarte, M.D.R. Pitta
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> There is some evidence to suggest that IL-9 production in Th17 cells is pathogenic during autoimmunity. It is believed that this cytokine may be associated with the pathogenesis of rheumatologic autoimmune diseases, including systemic lupuserythematosus (SLE) and rheumatoid arthritis (RA). <h3>Objectives</h3> The purpose of this article was to evaluate the levels of IL-9 in patients with SLE and RA compared with controls, and the association of IL-9 levels with clinical and laboratory parameters <h3>Methods</h3> This was a cross-sectional study were was assessed 117 SLE patients, 67 RA patients and 24 healthy controls by ELISA. Clinical and laboratory parameters were recorded. Statistic analyzes were performed by Graph Prism 3.02 software. <h3>Results</h3> The IL-9 serum levels were significantly higher in RA patients (4,77±3,618pg/ml) and in SLE patients (12,26±25,235 pg/ml) than in healthy individuals (1,22±0,706 pg/ml) (p&lt;0,001). In SLE patients, there were no statistically significant associations or correlations between the levels of IL-9 and SLEDAI, number of ACR criteria, organ damage, clinical manifestations, complement consumption and ANA or anti-DNA positivity, with exception of disease time, which showed a statistically significant negative correlation with IL-9 levels (r=-0,1948; p=0,0378). In RA patients no association or statistically significant correlation was observed with disease duration, DAS28, HAQ, rheumatoid factor positivity or erosions on radiography. <h3>Conclusions</h3> Few studies have evaluated the expression of Th9 cells or the levels of IL-9 in patients with autoimmune diseases, and it is unclear if there is an association with the pathogenesis of these diseases or if it is just an epiphenomenon. These data demonstrated increased serum levels of IL-9 in SLE and RA patients but further studies are needed to clarify the precise role of this cytokine and its potential use as therapeutic target. <h3>Disclosure of Interest</h3> None declared
Subglottic Stenosis
Authors: Yvonne Nussbaumer-Ochsner, Robert Thurnheer
Journal: New England Journal of Medicine (2015)

A 55-year-old woman presented with a history of exercise-induced dyspnea and intermittent wheezing. Examination revealed inspiratory stridor. Spirometry revealed a flattened inspiratory and expiratory flow-volume loop, and bronchoscopy revealed subglottic stenosis.
Thievery in Medical-School Libraries
Authors: E.J. H.
Journal: Annals of Internal Medicine (1971)

Editorials1 September 1971Thievery in Medical-School LibrariesE.J. H.E.J. H.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-75-3-469 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptEarly in 1970 the librarian of a medical school in Philadelphia announced to his faculty that the costs that year for replacing books and journals "missing" from its library would be an estimated $7,500 to $10,000, or 10% of the annual acquisitions budget. I could hardly believe his news. It implied that the students, or faculty, or other users of this library include some men and women with the morality of the shop lifter. But there was a grimmer possibility—that this blight might not be peculiar to this school but might be a plague in other American schools.In the...Reference1. ROBERTS M: Guards, turnstiles, electronic devices, and the illusion of security. College and Research Libraries 29:259-275, 1968 CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 September 1971Volume 75, Issue 3Page: 469-470KeywordsLibrariesPlague ePublished: 1 December 2008 Issue Published: 1 September 1971 PDF downloadLoading ...
Allergy and Anaphylaxis
Authors: Chantal Smeding, Laila E Gamadia, Jeroen Heidt
Journal: BMJ (1944)

Allergy is a medical condition of frequent occurrence. In the Netherlands approximately 20% of the population has some kind of respiratory allergy, due to pollen and dust mites. The occurrence of allergy on foods, antibiotics, other medications, contrast fluid and insect poison is estimated to be 2% in the adult population. Because of this large and diverse group of allergy triggers it is very likely that physicians, regardless of background or medical specialty, will come across questions regarding allergy at some point in their career. The severity of an allergic reaction can vary, with anaphylaxis as one of the most severe and potentially life-threatening reactions (among DRESS, SJS, TEN and acute FPIES). This article describes the backgrounds of IgE-mediated allergy and anaphylaxis, like pathophysiology, diagnostics and treatment.
Accuracy of the diagnoses of affective disorders and schizophrenia in public hospitals
Authors: A E Pulver, W T Carpenter, L Adler, J McGrath
Journal: American Journal of Psychiatry (1988)

The authors compared hospital diagnoses with best-estimate research diagnoses of affective disorders and schizophrenia for patients admitted to public psychiatric hospitals in Maryland. The concern that there is overdiagnosis of schizophrenia and underdiagnosis of affective disorders was not supported by this study.
Affective spectrum disorder: does antidepressant response identify a family of disorders with a common pathophysiology?
Authors: J I Hudson, H G Pope
Journal: American Journal of Psychiatry (1990)

Response to pharmacologic treatments may identify groups of disorders with a common pathophysiology. The authors applied a treatment-response model, based on four classes of antidepressants (tricyclic types, monoamine oxidase inhibitors, serotonin uptake inhibitors, and atypical agents), to the medical literature. The model identified eight disorders that may share a pathophysiologic abnormality: major depression, bulimia, panic disorder, obsessive-compulsive disorder, attention deficit disorder with hyperactivity, cataplexy, migraine, and irritable bowel syndrome. Phenomenologic and family studies support this grouping. If the model is validated, this family of disorders, which the authors term "affective spectrum disorder," would represent one of the most prevalent diseases in the population.
Radioiodine Uptake by Transplantable Tumors of the Thyroid Gland in C3H Mice. II. Theory
Authors: S H WOLLMAN
Journal: JNCI Journal of the National Cancer Institute (1953)

Journal Article Radioiodine Uptake by Transplantable Tumors of the Thyroid Gland in C3H Mice. II. Theory Get access S. H. Wollman S. H. Wollman National Cancer Institute2Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 13, Issue 4, February 1953, Pages 807–814, https://doi.org/10.1093/jnci/13.4.807 Published: 01 February 1953 Article history Received: 01 July 1952 Published: 01 February 1953
Reassessing Shark-Driven Trophic Cascades on Coral Reefs: A Reply to Ruppert et al .
Authors: George Roff, Christopher Doropoulos, Alice Rogers, Yves-Marie Bozec, Nils C. Krueck, Eleanor Aurellado, Mark Priest, Chico Birrell, Peter J. Mumby
Journal: Trends in Ecology & Evolution (2016)
Note on the Lack of Progressive Growth of Metastatic Mammary Carcinoma Transplanted Subcutaneously into Foreign Strains of Mice
Authors: R T PREHN
Journal: JNCI Journal of the National Cancer Institute (1950)

Journal Article Note on the Lack of Progressive Growth of Metastatic Mammary Carcinoma Transplanted Subcutaneously into Foreign Strains of Mice Get access Richmond T. Prehn Richmond T. Prehn senior assistant surgeon National Cancer Institute, National Institutes of Health, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 10, Issue 4, February 1950, Pages 893–894, https://doi.org/10.1093/jnci/10.4.893 Published: 01 February 1950 Article history Received: 07 November 1949 Published: 01 February 1950
Psychosis after neuroleptic withdrawal in a manic-depressive patient
Authors: J K Witschy, G L Malone, L D Holden
Journal: American Journal of Psychiatry (1984)

The authors present a case of neuroleptic-induced supersensitivity psychosis in a manic-depressive patient. They discuss the clinical differentiation of such a withdrawal psychosis from schizophrenic decompensation.
Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial.
Authors: Terufumi Kato, Takashi Seto, Makoto Nishio, Koichi Goto, Shinji Atagi, Yukio Hosomi, Noboru Yamamoto, Toyoaki Hida, Makoto Maemondo, Kazuhiko Nakagawa, Seisuke Nagase, Isamu Okamoto, Takeharu Yamanaka, Ryosuke Harada, Masahiro Fukuoka, Nobuyuki Yamamoto
Journal: Journal of Clinical Oncology (2014)

8005 Background: Despite the development of EGFR tyrosine kinase inhibitors, median progression-free survival (PFS) is only about 13 months in patients with EGFR mutation–positive NSCLC. However, results from the BeTa Lung study for a subgroup of patients with EGFR mutation suggest that EB may prolong PFS in these patients. Methods: Open-label randomized trial. Patients with stage 3b/4 or recurrent non-squamous EGFR mutation–positive NSCLC, ECOG performance status 0/1, and no previous chemotherapy were randomly allocated to receive EB (E, 150 mg/day; B, 15 mg/kg every 3 weeks) or E (150 mg/day) until disease progression or unacceptable toxicity. The primary endpoint was PFS determined by blinded independent review committee. Secondary endpoints included overall survival, objective response rate (ORR), safety, and quality of life. The planned sample size was 150, with an alpha error of 0.2 and a power of 80% for a target hazard ratio (HR) of 0.7. Results: From February 2011 to March 2012, 154 patients were enrolled (EB group, n = 77; E group, n = 77). There were no major differences in patient characteristics, including age, gender, stage, and EGFR mutation type, between the two groups. Median PFS was 16.0 months for EB and 9.7 months for E (HR, 0.54; 95% CI, 0.36–0.79; log-rank p = 0.0015). In the EGFR exon 19 deletion subgroup, median PFS was 18.0 months for EB and 10.3 months for E. In the L858R subgroup, median PFS was 13.9 months for EB and 7.1 months for E. ORR was 69.3% for EB and 63.6% for E. There were 3 and 1 complete responses to EB and E, respectively. Grade 3 or 4 rash was more common in the EB group (25.3% versus 19.5%). Grade 3 or 4 bleeding was more common in the EB group (2.7% versus 0.0%). However, most adverse events were manageable, and no new safety signals arose. Five patients experienced grade 1–3 interstitial lung disease, but there was no difference between the groups. One treatment-related death occurred in the E group. Conclusions: EB results in significantly longer PFS than E in patients with EGFR mutation–positive NSCLC. Clinical trial information: JapicCTI-111390.
HIV among injecting drug users in Europe: increasing trends in the East
Authors: L Wiessing, M J van de Laar, M C Donoghoe, B Guarita, D Klempová, P Griffiths
Journal: Eurosurveillance (2008)

The human immunodeficiency virus (HIV) epidemic among injecting drug users (IDUs) shows different developments in different parts of the European region. In the countries of the European Union (EU) and the European Free Trade Association (EFTA), the rates of reported newly diagnosed cases of HIV infection in IDUs are mostly at stable and low levels or in decline. In contrast, those rates increased in 2007 in many of the other (eastern) countries in the World Health Organization (WHO) European Region, suggesting that the HIV epidemic among IDUs in Europe is still growing. In countries or regions where indicators of HIV incidence show upward trends, existing prevention measures may be insufficient and in need of strengthening. In the EU/EFTA region the larger availability of harm reduction measures such as opioid substitution treatment and needle and syringe programmes may have played a key role in containing the epidemic among IDUs.